Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Postoperative de novo epilepsy after craniotomy a nationwide register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cyproterone acetate and risk of meningioma: a nationwide cohort study

    Research output: Contribution to journalLetterResearchpeer-review

  3. Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects

    Research output: Contribution to journalReviewResearchpeer-review

  4. Understanding the relationship between cognitive performance and function in daily life after traumatic brain injury

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The prognostic value of neurofilament light chain in serum

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Apparent changes in the epidemiology and severity of multiple sclerosis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

OBJECTIVE: To assess the risk of losing income from salaries and risk disability pension for multiple sclerosis patients with a clinically stable disease course 3 years after the start of disease-modifying therapy (DMT).

METHODS: Data from the Danish Multiple Sclerosis Registry were linked to other Danish nationwide population-based databases. We included patients who started treatment with a DMT between 2001 and 2014. Patients were categorised into a clinically stable group (No Evidence of Disease Activity (NEDA-2)) and a clinically active group (relapse activity or 6-month confirmed Expanded Disability Status Scale worsening). Outcomes were: (1) loss of regular income from salaries and (2) a transfer payment labelled as disability pension. We used a Cox proportional hazards model to estimate confounder-adjusted HRs, and absolute risks were plotted using cumulative incidence curves accounting for competing risks.

RESULTS: We included 2406 patients for the income analyses and 3123 patients for the disability pension analysis. Median follow-up from index date was ~5 years in both analyses. The NEDA-2 group had a 26% reduced rate of losing income (HR 0.74; 95% CI 0.60 to 0.92). HRs were calculated for 5-year intervals in the disability pension analysis: year 0-5: a 57% reduced rate of disability pension for the NEDA-2 group (HR 0.43; 95% CI 0.33 to 0.55) and year 5-10: a 36% reduced rate (HR 0.64; 95% CI 0.40 to 1.01).

CONCLUSION: Clinically stable disease course (NEDA-2) is associated with a reduced risk of losing income from salaries and a reduced risk of disability pension.

Original languageEnglish
JournalJournal of neurology, neurosurgery, and psychiatry
Volume91
Issue number1
Pages (from-to)67-74
Number of pages8
ISSN0022-3050
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • Adolescent, Adult, Databases, Factual, Denmark/epidemiology, Disability Evaluation, Disease Progression, Endpoint Determination, Female, Humans, Income, Male, Middle Aged, Multiple Sclerosis/economics, Pensions/statistics & numerical data, Recurrence, Registries, Risk Assessment, Salaries and Fringe Benefits, Young Adult

ID: 61515844